Skip to main content
    A

    Atrium Therapeutics, Inc. Common Stock (RNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.51
    +0.01 (+0.13%)

    Market Cap: $162.00M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Atrium Therapeutics, Inc. Common Stock (RNA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Atrium Therapeutics, Inc. Common Stock are Invivyd (IVVD), Anixa Biosciences (ANIX) and Codexis (CDXS). By market cap, Atrium Therapeutics, Inc. Common Stock ranks 6th of the 13 companies on this page; SAB Biotherapeutics (SABS) is the largest at $266.66M.

    Peer Comparison

    RNA's ROIC of -44.5% is above the peer median of -184.6%, and its revenue growth of 24.2% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Atrium Therapeutics, Inc. Common Stock (RNA)$162.00MN/A3.3x-180.9%-44.5%24.2%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Anixa Biosciences Inc (ANIX)$91.08MN/AN/A0.0%N/A0.0%0.00%
    Codexis Inc (CDXS)$127.13MN/AN/A-21.8%N/A124.0%0.00%
    SAB Biotherapeutics Inc (SABS)$266.66MN/AN/A0.0%N/A-62.4%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    PolyPid (PYPD)$132.25MN/AN/A0.0%N/A0.0%0.00%
    Pyxis Oncology Inc (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    OUTLOOK THERAPEUTICS INC (OTLK)$100.54MN/AN/A0.0%-776.9%-99.4%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    Armata Pharmaceuticals Inc (ARMP)$143.94MN/A14.7x0.0%-184.6%173.6%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Peer median$153.26MN/A14.7x0.0%-184.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Atrium Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Anixa Biosciences Inc (ANIX)
    Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
    ANIX competitors
    Codexis Inc (CDXS)
    Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
    CDXS competitors
    SAB Biotherapeutics Inc (SABS)
    SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
    SABS competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    PolyPid (PYPD)
    PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)...
    PYPD competitors
    Pyxis Oncology Inc (PYXS)
    Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)...
    PYXS competitors
    OUTLOOK THERAPEUTICS INC (OTLK)
    Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic...
    OTLK competitors
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    Armata Pharmaceuticals Inc (ARMP)
    Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment...
    ARMP competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors

    Frequently Asked Questions About RNA

    Who are Atrium Therapeutics, Inc. Common Stock's main competitors?

    The companies most similar to Atrium Therapeutics, Inc. Common Stock include Invivyd (IVVD), Anixa Biosciences (ANIX), Codexis (CDXS), SAB Biotherapeutics (SABS) and Palisade Bio (PALI), listed from the closest match.

    Who is Atrium Therapeutics, Inc. Common Stock's biggest competitor?

    SAB Biotherapeutics (SABS) is the largest of the similar companies at $266.66M; Invivyd (IVVD) is the closest match by business profile, size, sector and industry.

    How does RNA stock compare with its competitors?

    RNA's P/S is 3.3x against a peer median of 14.7x; its net margin is -180.9% against a peer median of 0.0%.

    Which of Atrium Therapeutics, Inc. Common Stock's competitors pays a higher dividend?

    Atrium Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Atrium Therapeutics, Inc. Common Stock bigger than its competitors?

    No. Atrium Therapeutics, Inc. Common Stock is 6th by market cap among the 13 companies on this page; the largest is SAB Biotherapeutics (SABS) at $266.66M.